Off-label use of bevacizumab linked to eye inflammation

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2009年 / 1234卷 / 1期
关键词：
Bevacizumab; Intraocular Pressure; Endophthalmitis; Metastatic Carcinoma; Safety Information;
D O I：
10.2165/00128415-200912340-00001
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 1
相关论文
共 50 条
  • [1] An Investigation of the Off-Label Use of Bevacizumab
    Liu, Tao
    Chen, Zhuo-Jia
    Lin, Zi-Chao
    Chen, Fu-Qin
    Huang, Hong-Bing
    [J]. LATIN AMERICAN JOURNAL OF PHARMACY, 2015, 34 (03): : 480 - 487
  • [2] Bevacizumab for blinding eye disease - is it time for the PBS to list for off-label use?
    Heyworth, Peter
    [J]. AUSTRALIAN HEALTH REVIEW, 2022, 46 (02) : 150 - 152
  • [3] Off-Label Drug Use: The Bevacizumab Story
    Stewart, Michael W.
    [J]. MAYO CLINIC PROCEEDINGS, 2013, 88 (03) : 305 - 305
  • [4] Bevacizumab (Avastin): Off-label Use in Ophthalmology
    Abukheir, Babiker H.
    [J]. SUDAN JOURNAL OF MEDICAL SCIENCES, 2008, 3 (01): : 71 - 73
  • [5] Off-label use of intravitreal bevacizumab: A global conundrum
    Singh, Samya
    Saxena, Sandeep
    Akduman, Levent
    Meyer, Carsten H.
    [J]. INDIAN JOURNAL OF OPHTHALMOLOGY, 2024, 72 (05) : 617 - 619
  • [6] Bevacizumab/sirolimusLack of efficacy and off-label use: case report
    [J]. Reactions Weekly, 2022, 1913 (1) : 118 - 118
  • [7] Off-label use of antipsychotics: Rethinking "off-label"
    Groleger, Urban
    [J]. PSYCHIATRIA DANUBINA, 2007, 19 (04) : 350 - 353
  • [8] Off-label use of bevacizumab in the treatment of retinal disease: ethical implications
    Rohowetz, Landon James
    [J]. JOURNAL OF MEDICAL ETHICS, 2019, 45 (10) : 668 - 672
  • [9] Bevacizumab/yttrium-90-DOTATOCLack of efficacy and off-label use
    [J]. Reactions Weekly, 2024, 2006 (1) : 139 - 139
  • [10] Assessment of the off-label use of intravitreal bevacizumab therapy for macular edema
    Castellanos, Yolanda
    Carpio, Rafael
    Garcia, Mario
    Ontanon, Ana
    Candel, Beatriz
    Farfan, Francisco J.
    [J]. PHARMACY WORLD & SCIENCE, 2008, 30 (05): : 694 - 694
12345